Ignite Creation Date:
2025-12-24 @ 3:41 PM
Ignite Modification Date:
2025-12-28 @ 12:10 AM
Study NCT ID:
NCT00127192
Status:
COMPLETED
Last Update Posted:
2015-06-15
First Post:
2005-08-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Study Overview
Official Title:
Sitagliptin (MK0431) Late Phase II Double-Blind Dose-Response Study - Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: